Biomarin Pharmaceutical (BMRN) Debt Ratio (2012 - 2026)

Biomarin Pharmaceutical's (BMRN) quarterly Debt Ratio came in at 0.17 in Q1 2026, up 111.71% on a QoQ basis from 0.08 in Q4 2025.

Biomarin Pharmaceutical (BMRN) Debt Ratio (2012 - 2026) Analysis & Trends

Biomarin Pharmaceutical (BMRN) has 14 years of Debt Ratio data on file, last reported at 0.17 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.17 (changed N/A YoY) and the FY2025 annual result came in at 0.08, changed N/A from the prior year.
Debt Ratio advanced to 0.17 in Q1 2026, from 0.08 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.17 in Q1 2026 to a low of 0.0 in Q4 2022.
A 5-year average of 0.05 and a median of 0.07 in 2024 frame the typical range for Debt Ratio.
Annual changes were most pronounced in 2022 — Debt Ratio plunged 68.9% — and 2023, when it surged 2789.79%.
Tracing BMRN's Debt Ratio over 5 years: stood at 0.0 in 2022, then surged by 2789.79% to 0.07 in 2023, then declined by 3.0% to 0.07 in 2024, then gained by 12.31% to 0.08 in 2025, then surged by 111.71% to 0.17 in 2026.
The last three Debt Ratio figures came in at 0.17 (Q1 2026), 0.08 (Q4 2025), and 0.07 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Biomarin Pharmaceutical	13.04 Bn	12.16 Bn	786.91 Mn	0.41

Download Data